May Health, a clinical-stage medical device company dedicated to helping those living with the endocrine disorder polycystic ovary syndrome (PCOS), announced it has closed a $25 million Series B financing round, co-led by Bpifrance and Trill Impact with participation from founding investor Sofinnova Partners, and Avestria Ventures and Kidron Capital Assets LP.
The funds will support the company’s growth and advance its Ovarian Rebalancing therapy through the pivotal REBALANCE Study, which evaluates its potential to address PCOS-related infertility.
In connection with the funding, Nina Rawal, co-head and partner at Trill Impact Ventures Advisory, and Jean-Francois Morin, investment director at Bpifrance, will join May Health’s Board of Directors.
PCOS affects about 10% of women. And it is a severe and lifelong endocrine condition caused by hormone imbalance and the leading cause of female infertility. For women with PCOS, there is a local dysregulation of androgens as compared to estrogens in the ovary, leading to inconsistent ovulation.
Along with being a common cause of infertility, PCOS is associated with increased insulin resistance, Type 2 diabetes, heart disease and stroke. PCOS can also present challenging day-to-day struggles with irregular menstruation, acne, thinning scalp hair, excessive body hair growth, high blood pressure, and sleep apnea.
Ovarian Rebalancing is an investigational treatment created to restore women’s natural ovulation cycles. The straightforward, one-time in-office procedure induces ovulation through targeted ablation of ovarian tissue using radiofrequency (RF) energy.
KEY QUOTES:
“For the millions of women living with PCOS, the physical and emotional impact of this condition is profound. From fertility challenges to emotional well-being and physical symptoms, women with PCOS need more viable treatment options. We are thankful to Bpifrance and Trill Impact for co-leading this financing round, together with our founding investor Sofinnova Partners, and to our deep bench of supporters and advisors for their confidence in our team and growth strategy. We are eager to continue building on the positive results of our previous clinical studies as well as this financing milestone as we work to become a leader in global women’s health and PCOS-related infertility.”
– Anne Morrissey, CEO of May Health
“We see May Health as a great example of a company where commercial opportunity and impact go hand in hand. Trill Impact is excited to collaborate with the May Health team and its strong shareholders to bring their innovative product to women who have suffered from a lack of treatment options for too long.”
– Nina Rawal, co-head and partner at Trill Impact Ventures
“May Health is charting a new path in fertility care for women with PCOS with its innovative Ovarian Rebalancing therapy. We are thrilled to support the company’s effort to bring its new approach to women with PCOS, including advancing it in the pivotal REBALANCE Study. With its unique mechanism of action, May Health’s device has the potential to significantly improve the lives of patients with PCOS, including but not limited to related infertility issues. We are committed to supporting May Health to become a leader in the PCOS space.”
– Jean-François Morin, investment director at Bpifrance
“The May Health team, led by highly accomplished leaders in women’s health, has been dedicated to bringing new treatment options to women with PCOS. We’ve been steadfast supporters of May Health from the time of the company’s inception by our MD Start medtech accelerator team in 2017 and are delighted to see Bpifrance and Trill Impact Ventures co-leading the Series B financing round, joining us in championing May Health’s mission and recognizing the transformative potential of Ovarian Rebalancing.”
– Antoine Papiernik, chairman and managing partner at Sofinnova Partners and previous chairman of the May Health board
“For years, women with PCOS who struggle with infertility have sought alternative treatment options that go beyond IVF and laparoscopic ovarian drilling. Our team is working to develop a simple and safe procedure that can activate natural ovulation and help women regain their ability to grow their families. We’re thankful to our investment partners for their support and look forward to further research of Ovarian Balancing in the REBALANCE Study.”
– Dr. Robert Auerbach, OBGYN, chairman of the May Health board
